BAXTER INTL INC shareholders Q3 2023

BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 885 filers reported holding BAXTER INTL INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.

BAXTER INTL INC shareholders Q3 2023
NameSharesValueWeighting ↓
Cullen Capital Management, LLC 1,234,199$46,578,6700.54%
SHEPHERD KAPLAN KROCHUK, LLC 16,105$607,8040.53%
Sonen Capital LLC 7,096$267,8030.53%
Banco de Sabadell, S.A 15,868$5990.52%
Cannell & Co. 393,293$14,842,8780.51%
White Knight Strategic Wealth Advisors, LLC 10,178$384,1180.51%
OFI INVEST ASSET MANAGEMENT 392,702$13,998,1800.50%
CINCINNATI INSURANCE CO 672,000$25,361,2800.50%
SEARLE & CO. 33,752$1,273,8000.43%
JOHN G ULLMAN & ASSOCIATES INC 69,829$2,635,3460.43%
Carmel Capital Partners, LLC 24,743$933,8030.42%
Alan B Lancz & Associates, Inc. 9,600$362,3040.41%
OLD POINT TRUST & FINANCIAL SERVICES N A 24,161$911,8360.41%
MACQUARIE GROUP LTD 8,360,392$315,521,5510.40%
Ally Financial Inc. 71,000$2,679,5400.39%
Foundry Partners, LLC 157,752$5,953,5600.37%
GUARDIAN CAPITAL ADVISORS LP 100,720$3,297,5730.37%
Berkeley Capital Partners, LLC 26,890$1,014,8400.37%
Horrell Capital Management, Inc. 29,130$1,0990.37%
EVERETT HARRIS & CO /CA/ 605,854$22,864,9180.36%
About BAXTER INTL INC

Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.

Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.

Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.

Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.

Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BAXTER INTL INC's shareholders in Q3 2023. To view BAXTER INTL INC's shareholder history, click here.